Development of a lower-sodium oxybate formulation for the treatment of patients with narcolepsy and idiopathic hypersomnia
Development of a lower-sodium oxybate formulation for the treatment of patients with narcolepsy and idiopathic hypersomnia is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Development of a lower-sodium oxybate formulation for the treatment of patients with narcolepsy and idiopathic hypersomnia have?
Development of a lower-sodium oxybate formulation for the treatment of patients with narcolepsy and idiopathic hypersomnia has 23 citations in the OpenAlex counts ScholarIQ stores.
When was Development of a lower-sodium oxybate formulation for the treatment of patients with narcolepsy and idiopathic hypersomnia published?
Development of a lower-sodium oxybate formulation for the treatment of patients with narcolepsy and idiopathic hypersomnia has 2021 year in the ScholarIQ index.
What is the open-access status of Development of a lower-sodium oxybate formulation for the treatment of patients with narcolepsy and idiopathic hypersomnia?
Development of a lower-sodium oxybate formulation for the treatment of patients with narcolepsy and idiopathic hypersomnia has bronze oa status in the ScholarIQ index.
What is the DOI of Development of a lower-sodium oxybate formulation for the treatment of patients with narcolepsy and idiopathic hypersomnia?
The DOI for Development of a lower-sodium oxybate formulation for the treatment of patients with narcolepsy and idiopathic hypersomnia is on the source record.
What is the PMID of Development of a lower-sodium oxybate formulation for the treatment of patients with narcolepsy and idiopathic hypersomnia?
The PMID for Development of a lower-sodium oxybate formulation for the treatment of patients with narcolepsy and idiopathic hypersomnia is on the source record.
What is the OpenAlex record for Development of a lower-sodium oxybate formulation for the treatment of patients with narcolepsy and idiopathic hypersomnia?
The OpenAlex for Development of a lower-sodium oxybate formulation for the treatment of patients with narcolepsy and idiopathic hypersomnia is on the source record.